It seems that Monsanto and the DOD have teamed up to invest in an Ebola virus treatment company. Monsanto, the company that has given us Agent Orange, Roundup pesticide, and GMO food, is now working to give us an Ebola vaccine. What is Monsanto’s gain one must ask. The deal is, the seed money Monsanto will contribute begins at $1.5 million. The value of the deal has the potential to grow to an estimated $86 million dollars.
Monday, Fox news reported that “The experimental drug used to treat two American aid workers who have been infected with the Ebola virus has never been tested on humans before and was only identified earlier this year as part of an ongoing research program backed by the U.S. government and military.”
Fox also said, “The Defense Department has long had a hand in researching infectious diseases, including Ebola. During much of the Cold War period this served two purposes: to keep abreast of diseases that could limit the effectiveness of troops deployed abroad and to be prepared if biological agents were used as weapons.” It was also stated that the U.S. military currently has no biological weapons program.
But not to worry, a new player has entered the ring. It seems that Monsanto and the DOD have teamed up to invest in an Ebola virus treatment company. Monsanto, the company that has given us Agent Orange, Roundup pesticide, and GMO food, is now working to give us an Ebola vaccine. What is Monsanto’s gain one must ask. The deal is, the seed money Monsanto will contribute begins at $1.5 million. The value of the deal has the potential to grow to an estimated $86 million dollars. The company’s name is Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics. “TKM-Ebola, an anti-Ebola virus RNAi therapeutic, is being developed under a $140 million contract with the U.S. Department of Defense’s Medical Countermeasure Systems BioDefense Therapeutics (MCS-BDTX) Joint Product Management Office”. That’s a pretty sweet deal by anyone’s calculations.
Another interesting fact is that U.S. Centers for Disease Control owns a patent on a particular strain of Ebola known as “EboBun.” It’s patent No. CA2741523A1 and it was awarded in 2010. A patent is a form of intellectual property that allows the patent holder to control the use of a product or method of doing something. That control includes the ability to charge royalties for its use. According to Canadian patent lawyer David Schwartz, “‘You can’t patent a disease condition per se, such as cancer or influenza. But if you’re talking about patenting a life form like a bacteria or virus, if altered by man, the answer there is yes.”
If you take David Schwartz at his word, that means that the virus has to be altered or modified from it’s original chemical composition in order to be patented. That means that the strain of the virus that is currently patented was essentially created or man-made. Who better to aid in the creation of a Frankenstein vaccine for the created Ebola virus than Monsanto?
Make no mistake that billions of dollars in profits for Monsanto are at stake in all this. Shares of Tekmira surged over 11% last Friday as pressure was placed on the FDA to fast-track Ebola vaccine trials the company has set up. “Health campaigners have started a petition which has already been signed by approximately 15,500 people on change.org pressurizing FDA to approve the drug in the minimum possible time frame,” reports BidnessEtc.com. //Mike Adams N.N.
To borrow a play from the president’s playbook, the FDA can be circumvented. Once a public health emergency is declared by WHO, untested experimental vaccines can be given to populations. There’s just something wrong with this whole picture.